Attenuation of food intake in chicks by an inverse agonist of cannabinoid receptor 1 administered by either injection or ingestion in hydrocolloid carriers

2011 ◽  
Vol 170 (3) ◽  
pp. 522-527 ◽  
Author(s):  
Nataly Novoseletsky ◽  
Amos Nussinovitch ◽  
Miriam Friedman-Einat
Obesity ◽  
2008 ◽  
Vol 16 (11) ◽  
pp. 2451-2455 ◽  
Author(s):  
Marianne F. Bennetzen ◽  
Maria P. Nielsen ◽  
Bjørn Richelsen ◽  
Steen B. Pedersen

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3587
Author(s):  
Isabel van Ackern ◽  
Angela Kuhla ◽  
Björn Kuhla

The endocannabinoid system (ECS) plays a pivotal role in the complex control and regulation of food intake. Pharmacological ECS activation could improve health in energy-deficient stages by increasing food intake, at least in intermittent feeders. However, knowledge of the mechanism regulating appetite in species with continued nutrient delivery is incomplete. The objectives of this pilot study were to investigate the effect of the intraperitoneal (i.p.) administration of the endocannabinoids (ECs) anandamide (AEA) and 2-arachidonoylglycerol (2-AG) on food intake, plasma EC concentrations and hypothalamic orexigenic signaling, and to study how the circulatory EC tone changes in response to short-term food deprivation in dairy cows, a species with continuous nutrient delivery. The administration of EC resulted in higher food intake during the first hour after treatment. Plasma AEA concentrations were significantly increased 2.5 h after AEA injection, whereas plasma 2-AG concentrations remained unchanged 2.5 h after 2-AG injection. The hypothalamic immunoreactivity of cannabinoid receptor 1, agouti-related protein, and orexin-A was not affected by either treatment; however, neuropeptide Y and agouti-related protein mRNA abundances were downregulated in the arcuate nucleus of AEA-treated animals. Short-term food deprivation increased plasma 2-AG, while plasma AEA remained unchanged. In conclusion, i.p.-administered 2-AG and AEA increase food intake in the short term, but only AEA accumulates in the circulation. However, plasma 2-AG concentrations are more responsive to food deprivation than AEA.


2015 ◽  
Vol 17 (5) ◽  
pp. 495-504 ◽  
Author(s):  
W.-C. Hsiao ◽  
K.-S. Shia ◽  
Y.-T. Wang ◽  
Y.-N. Yeh ◽  
C.-P. Chang ◽  
...  

Endocrinology ◽  
2011 ◽  
Vol 152 (10) ◽  
pp. 3661-3667 ◽  
Author(s):  
Sarah Haas Lockie ◽  
Traci A. Czyzyk ◽  
Nilika Chaudhary ◽  
Diego Perez-Tilve ◽  
Stephen C. Woods ◽  
...  

Existing monotherapies for the treatment of obesity provide only modest weight loss and/or have adverse side effects, and this is also the case with the cannabinoid receptor 1 (CB1) inverse agonist, rimonabant. We aimed to investigate the possibility of improving efficacy and reducing side effects of rimonabant by cotreatment with opioid system antagonists. Using both genetic and pharmacological removal of opioid signaling in mice, we investigated changes in body weight, food intake, and fat mass as well as behavioral outcomes of interactions between opioid ligands and the CB1 using the inverse agonist, rimonabant. The ability of rimonabant to reduce weight is enhanced by removal of with μ-opioid receptor signaling, while not being greatly affected by κ-opioid receptor blockade. Additionally, lack of opioid signaling, especially κ-opioid receptor, attenuated the ability of rimonabant to decrease immobility time in the Porsolt forced-swim test, a preclinical model of depression. These results indicate that the endogenous opioid system is involved in modulating both the metabolic and mood effects of rimonabant.


2020 ◽  
Vol 29 (7) ◽  
pp. 616-622 ◽  
Author(s):  
Attila Oláh ◽  
Majid Alam ◽  
Jérémy Chéret ◽  
Nikolett Gréta Kis ◽  
Zoltán Hegyi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document